Bufalin is a major
cardiotonic compound in the
traditional Chinese medicine,
Chansu, prepared from toad skin secretions. Cell culture studies have suggested an anticancer potential involving multiple cellular processes, including differentiation, apoptosis, senescence, and angiogenesis. In
prostate cancer cell models, P53-dependent and independent
caspase-mediated apoptosis and
androgen receptor (AR) antagonism have been described for
bufalin at micromolar concentrations. Because a human pharmacokinetic study indicated that single nanomolar
bufalin was safely achievable in the peripheral circulation, we evaluated its cellular activity within range with the AR-positive and P53 wild-type human LNCaP
prostate cancer cells in vitro Our data show that
bufalin induced
caspase-mediated apoptosis at 20 nmol/L or higher concentration with concomitant suppression of AR
protein and its best-known target, PSA and
steroid receptor coactivator 1 and 3 (SRC-1, SRC-3).
Bufalin exposure induced
protein abundance of P53 (not
mRNA) and P21CIP1 (CDKN1A), G2 arrest, and increased senescence-like phenotype (SA-
galactosidase). Small RNAi knocking down of P53 attenuated
bufalin-induced senescence, whereas knocking down of P21CIP1 exacerbated
bufalin-induced
caspase-mediated apoptosis. In vivo, daily
intraperitoneal injection of
bufalin (1.5 mg/kg
body weight) for 9 weeks delayed LNCaP subcutaneous xenograft
tumor growth in NSG SCID mice with a 67% decrease of final weight without affecting
body weight.
Tumors from
bufalin-treated mice exhibited increased phospho-P53 and SA-
galactosidase without detectable
caspase-mediated apoptosis or suppression of AR and PSA. Our data suggest potential applications of
bufalin in
therapy of
prostate cancer in patients or chemo-interception of prostate precancerous lesions, engaging a selective activation of P53 senescence. Mol
Cancer Ther; 17(11); 2341-52. ©2018 AACR.